Advertisement
Canada markets closed

  • S&P/TSX

    21,875.79
    -66.41 (-0.30%)
     

  • S&P 500

    5,460.48
    -22.39 (-0.41%)
     

  • DOW

    39,118.86
    -45.24 (-0.12%)
     

  • CAD/USD

    0.7312
    +0.0011 (+0.15%)
     

  • CRUDE OIL

    81.46
    -0.28 (-0.34%)
     

  • Bitcoin CAD

    84,709.74
    +1,301.99 (+1.56%)
     

  • CMC Crypto 200

    1,281.21
    -2.62 (-0.20%)
     

  • GOLD FUTURES

    2,336.90
    +0.30 (+0.01%)
     

  • RUSSELL 2000

    2,047.69
    +9.35 (+0.46%)
     

  • 10-Yr Bond

    4.3430
    +0.0550 (+1.28%)
     

  • NASDAQ

    17,732.60
    -126.10 (-0.71%)
     

  • VOLATILITY

    12.44
    +0.20 (+1.63%)
     

  • FTSE

    8,164.12
    -15.56 (-0.19%)
     

  • NIKKEI 225

    39,583.08
    +241.58 (+0.61%)
     

  • CAD/EUR

    0.6820
    +0.0003 (+0.04%)
     

Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference

PR Newswire
·1 min read

CAMBRIDGE, Mass., June 27, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will participate in the H.C. Wainwright 3rd Annual Kidney Virtual Conference on Monday, July 15, 2024. Mr. Butler will present at 9:30 a.m. ET to provide updates on the progress of commercial launch activities for Vafseo® (vadadustat) Tablets.

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.)
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.)

A webcast of the presentation can be accessed through the "Investors" section of Akebia's website at https://ir.akebia.com for 30 days following the conference.

About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

ADVERTISEMENT

Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com

 

Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/akebia-therapeutics-to-present-at-the-hc-wainwright-3rd-annual-kidney-virtual-conference-302184495.html

SOURCE Akebia Therapeutics, Inc.